Olmesartanmedoxomil/Amlodipine Accord (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxil, the active ingredient in Olmesartan/Amlodipine Accord, is an angiotensin II receptor blocker presented as a tablet for oral use. It is combined with amlodipine, a calcium‑channel blocker, to treat hypertension in adults when monotherapy is insufficient.

GNH USA supplies Olmesartan/Amlodipine Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan/Amlodipine Accord is a fixed‑dose combination that targets the renin‑angiotensin system and vascular smooth‑muscle calcium channels to control high blood pressure. - Hypertension: provides additive blood‑pressure reduction for patients not adequately controlled on a single agent. - Essential hypertension: achieves target systolic and diastolic pressures with once‑daily dosing. - Resistant hypertension (as adjunct): offers an alternative pathway when additional agents are needed.

Adverse reactions may occur with any antihypertensive therapy.

Common Side Effects: - Dizziness: transient light‑headedness, especially after the first dose. - Headache: mild to moderate intensity, often resolves with continued use. - Peripheral edema: swelling of ankles or feet due to vasodilation. - Flushing: temporary warmth and reddening of the skin. - Fatigue: general tiredness without exertion. - Palpitations: awareness of heartbeat, usually benign.

Serious or Rare Side Effects: - Angioedema: rapid swelling of face, lips, tongue, or airway requiring emergency care. - Severe hypotension: marked drop in blood pressure leading to fainting or shock. - Hepatic dysfunction: abnormal liver enzymes or jaundice. - Myocardial infarction: rare occurrence of heart attack, especially in patients with existing coronary disease.

Before initiating therapy, consider patient‑specific factors and monitor for adverse events. - Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic impairment: use with caution; monitor liver enzymes. - Pregnancy: contraindicated due to risk of fetal toxicity; avoid in women of child‑bearing potential. - Elderly: start at the lowest dose and titrate slowly. - Electrolyte imbalance: monitor serum potassium, especially when combined with diuretics. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Olmesartan/Amlodipine may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - ACE inhibitors: combined use can increase risk of hyperkalemia and renal dysfunction. - Potassium‑sparing diuretics: may precipitate dangerous hyperkalemia. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): raise amlodipine plasma levels, increasing hypotension risk. - NSAIDs: can blunt antihypertensive effect and affect renal function.

Moderate Interactions (Monitor Closely): - Thiazide or loop diuretics: additive blood‑pressure lowering; monitor for volume depletion. - Other antihypertensives: may enhance hypotensive effect; adjust dose as needed. - Rifampin: induces CYP3A4, reducing amlodipine concentrations. - Grapefruit juice: can increase amlodipine exposure; advise limited consumption.